AKBA Akebia Therapeutics Inc.

18.00
-0.19  -1%
Previous Close 18.19
Open 18.29
Price To book 14.88
Market Cap 848725722
Shares 47,151,429
Volume 248,229
Short Ratio 5.71
Av. Daily Volume 408,958

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 2H 2017 with data due by the end of 2018.
Vadadustat - TRILO2GY
Three-times-weekly dosing regimen for vadadustat
Phase 2 data due by the end of 2018.
Vadadustat - FO2RWARD
Renal anemia
Phase 3 initiated August 2016. NDA filing pending positive data due 2019. Estimate data release mid-2019.
Vadadustat - INNO2VATE
Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD)
Phase 3 initiated January 2016. NDA filing pending positive data due 2019. Estimate data release mid-2019.
Vadadustat - PRO2TECT
Non-dialysis patients with anemia related to CKD (NDD-CKD)

Latest News

  1. Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
  2. Axovant Shares Plummet On Alzheimer's Data; Genocea Gets Rocked -Biotech Movers
  3. Akebia Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Non-Dialysis-Dependent Chronic Kidney Disease
  4. Ex-Akebia employee suspected of insider trading re-arrested
  5. BioMarin Presents Interim Data on BMN 250 from Phase I/II
  6. Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge
  7. Akebia to Present at Upcoming Investor Conferences
  8. Featured Company News - ContraVir Announces Issuance of New US Patent for Expansion of Cyclophilin Inhibitor Program
  9. Akebia Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : AKBA-US : August 14, 2017
  10. Akebia Therapeutics reports 2Q loss
  11. Akebia Announces Second Quarter 2017 Financial Results
  12. ETFs with exposure to Akebia Therapeutics, Inc. : July 24, 2017
  13. Ex-Akebia employee faces losing bail in insider trading case
  14. Akebia Therapeutics, Inc. – Value Analysis (NASDAQ:AKBA) : July 12, 2017
  15. Akebia Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : AKBA-US : July 11, 2017
  16. Akebia Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters
  17. Biotech Movers: Akebia Shares Down After Pricing Stock Offering